On October 8, Veradermics, Inc. rose 17.35% in regular trading, trading at $130.215/share with a turnover of $289 million, marking its largest single-day gain since April. The rally followed ongoing positive clinical progress for its lead candidate VDPHL01, an oral non-hormonal therapy for patterned hair loss. Recent data from a Phase 2 trial in females showed up to 90.0% of subjects achieved improved or much improved hair coverage at six months, with a favorable safety profile and no treatment-related serious adverse events. Earlier Phase 2/3 data in males also met all primary and key secondary endpoints with statistical significance. The company holds cash reserves of $819.9 million, expected to fund operations through 2030 and cover multiple Phase 3 readouts and potential commercialization of VDPHL01.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)